Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

Circulation

Volumn 136, Issue 3, 2017, Pages 249-259

  Kosiborod, Mikhail ^a   Cavender, Matthew A ^b   Fu, Alex Z ^c   Wilding, John P ^d   Khunti, Kamlesh ^e   Holl, Reinhard W ^f   Norhammar, Anna ^g   Birkeland, Kåre I ^h,i   Jørgensen, Marit Eika ^j,k   Thuresson, Marcus ^l   Arya, Niki ^m   Bodegård, Johan ^m   Hammar, Niklas ^g,m   Fenici, Peter ^m  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f UNIVERSITY OF ULM   (Germany)

^g KAROLINSKA INSTITUTE   (Sweden)

^h UNIVERSITY OF OSLO   (Norway)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j STENO DIABETES CENTER   (Denmark)

^k UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^l STATISTICON AB   (Sweden)

^m ASTRAZENECA   (United Kingdom)

more..

Author keywords

canagliflozin; dapagliflozin; death; diabetes mellitus; empagliflozin; heart failure; sodium glucose transporter 2

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; ARTICLE; CARDIOVASCULAR RISK; DEATH; DENMARK; EFFECT SIZE; FEMALE; FOLLOW UP; GERMANY; HAZARD RATIO; HEART FAILURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; NORWAY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROPENSITY SCORE; REGISTER; SWEDEN; UNITED KINGDOM; UNITED STATES; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; EPIDEMIOLOGY; GLUCOSE BLOOD LEVEL; INTERNATIONAL COOPERATION; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; TRENDS;

AGED; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CANAGLIFLOZIN; DENMARK; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GERMANY; GLUCOSIDES; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INTERNATIONALITY; MALE; MIDDLE AGED; MORTALITY; NORWAY; REGISTRIES; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; SWEDEN; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES;

EID: 85019731757     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.029190     Document Type: Article

References (39)

1. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215-2222. doi: 10.1016/S0140-6736(10)60484-9.
2. Schocken DD, Benjamin EJ, Fonarow GC, Krumholz HM, Levy D, Mensah GA, Narula J, Shor ES, Young JB, Hong Y; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; Functional Genomics and Translational Biology Interdisciplinary Working Group. Prevention of heart failure: A scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008;117:2544-2565. doi: 10.1161/CIRCULATIONAHA.107.188965.
3. Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, O'Keeffe LM, Gao P, Wood AM, Burgess S, Freitag DF, Pennells L, Peters SA, Hart CL, Håheim LL, Gillum RF, Nordestgaard BG, Psaty BM, Yeap BB, Knuiman MW, Nietert PJ, Kauhanen J, Salonen JT, Kuller LH, Simons LA, van der Schouw YT, Barrett-Connor E, Selmer R, Crespo CJ, Rodriguez B, Verschuren WM, Salomaa V, Svärdsudd K, van der Harst P, Björkelund C, Wilhelmsen L, Wallace RB, Brenner H, Amouyel P, Barr EL, Iso H, Onat A, Trevisan M, D'Agostino RB Sr, Cooper C, Kavousi M, Welin L, Roussel R, Hu FB, Sato S, Davidson KW, Howard BV, Leening MJ, Leening M, Rosengren A, Dörr M, Deeg DJ, Kiechl S, Stehouwer CD, Nissinen A, Giampaoli S, Donfrancesco C, Kromhout D, Price JF, Peters A, Meade TW, Casiglia E, Lawlor DA, Gallacher J, Nagel D, Franco OH, Assmann G, Dagenais GR, Jukema JW, Sundström J, Woodward M, Brunner EJ, Khaw KT, Wareham NJ, Whitsel EA, Njølstad I, Hedblad B, Wassertheil-Smoller S, Engström G, Rosamond WD, Selvin E, Sattar N, Thompson SG, Danesh J; Emerging Risk Factors Collaboration. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314:52-60. doi: 10.1001/jama.2015.7008.
4. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol. 1974;34:29-34.
5. IDF Diabetes Atlas Group. Update of mortality attributable to diabetes for the IDF diabetes atlas: Estimates for the year 2011. Diabetes Res Clin Pract. 2013;100:277-279. doi:10.1016/j.diabres.2013.02.005.
6. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513-1530. doi:10.1016/S0140-6736(16)00618-8.
7. Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjörnsdottir S, Wedel H, Clements M, Dahlqvist S, Lind M. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373:1720-1732. doi: 10.1056/NEJMoa1504347.
8. Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S, Kuder J, Im K, Wilson PW, Bhatt DL; REACH Registry Investigators. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: Outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2015;132:923-931. doi: 10.1161/CIRCULATIONAHA.114.014796.
9. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME® trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPAREG OUTCOME® trial. Eur Heart J. 2016;37:1526-1534. doi: 10.1093/eurheartj/ehv728.
10. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232-242. doi: 10.1056/NEJMoa1501352.
11. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27:699-703.
12. Matsushita K, Blecker S, Pazin-Filho A, Bertoni A, Chang PP, Coresh J, Selvin E. The association of hemoglobin A1c with incident heart failure among people without diabetes: The atherosclerosis risk in communities study. Diabetes. 2010;59:2020-2026. doi: 10.2337/db10-0165.
13. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi: 10.1056/NEJMoa1504720.
14. Håheim LL, Helgeland J. Agreement between referral information and discharge diagnoses according to Norwegian elective treatment guidelines -a cross-sectional study. BMC Health Serv Res. 2014;14:493. doi: 10.1186/s12913-014-0493-5.
15. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450. doi: 10.1186/1471-2458-11-450.
16. Norhammar A, Bodegard J, Nystrom T, Thuresson M, Eriksson JW, Nathanson D. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: A nationwide study in Sweden, 2006-2013. Diabetologia. 2016;59:1692-1701. doi:10.1007/s00125-016-3971-y.
17. Sundbøll J, Adelborg K, Munch T, Frøslev T, Sørensen HT, Bøtker HE, Schmidt M. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: A validation study. BMJ Open. 2016;6:e012832. doi: 10.1136/bmjopen-2016-012832.
18. Lee DS, Donovan L, Austin PC, Gong Y, Liu PP, Rouleau JL, Tu JV. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005;43:182-188.
19. Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ; PARADIGM-HF Investigators and Committees,. Importance of clinical worsening of heart failure treated in the outpatient setting: Evidence from the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). Circulation. 2016;133:2254-2262. doi: 10.1161/CIRCULATIONAHA.115.020729.
20. Brynildsen J, Høiseth AD, Nygård S, Hagve TA, Christensen G, Omland T, Røsjø H. [Diagnostic accuracy for heart failure -data from the Akershus Cardiac Examination 2 Study]. Tidsskr Nor Laegeforen. 2015;135:1738-1744. doi: 10.4045/tidsskr.14.1174.
21. Kümler T, Gislason GH, Kirk V, Bay M, Nielsen OW, Køber L, Torp-Pedersen C. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail. 2008;10:658-660. doi: 10.1016/j.ejheart.2008.05.006.
22. Ingelsson E, Arnlöv J, Sundström J, Lind L. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail. 2005;7:787-791. doi: 10.1016/j.ejheart.2004.12.007.
23. Stuart EA. Matching methods for causal inference: A review and a look forward. Stat Sci. 2010;25:1-21. doi: 10.1214/09-STS313.
24. Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD, McNeil BJ. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: A matched analysis using propensity scores. J Clin Epidemiol. 2001;54:387-398.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
26. Viechtbauer W. Conducting meta-analyses in r with the metafor package. J Stat Softw. 2010;36:1-48.
27. Hernán MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, Manson JE, Robins JM. Observational studies analyzed like randomized experiments: An application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19:766-779. doi: 10.1097/EDE.0b013e3181875e61.
28. Hernán MA, Hernández-Díaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9:48-55. doi: 10.1177/1740774511420743.
29. Prentice RL, Pettinger M, Anderson GL. Statistical issues arising in the Women's Health Initiative. Biometrics. 2005;61:899-911; discussion 911. doi: 10.1111/j.0006-341X.2005.454-1.x.
30. Neal B, Perkovic V, Mahaffey KW, Fulcher G, Erondu N, Desai M, Shaw W, Law G, Walton MK, Rosenthal N, de Zeeuw D, Matthews DR, on behalf of the CANVAS Program collaborative group. Optimising the analysis strategy for the canvas program -a pre-specified plan for the integrated analyses of the canvas and canvas-r trials. Diabetes Obes Metab. 2017. doi: 10.1111/dom.12924.
31. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM. Real-world evidence - what is it and what can it tell us?. N Engl J Med. 2016;375:2293-2297. doi: 10.1056/NEJMsb1609216.
32. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health, Center for Biologics Evaluation and Research. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices. Draft Guidance for Industry and Food and Drug Administration Staff. Rockville, MD: Food and Drug Administration; September 16, 2016. https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm513027.pdf. Accessed May 12, 2017.
33. European Commission. Directorate-General for Health and Food Safety. STAMP Commission Expert Group. Real world evidence. Brussels, Belgium: European Commission; March 10, 2016. http://ec.europa.eu/health//sites/health/files/files/committee/stamp/2016-03-stamp4/4-real-world-evidence- background-paper.pdf. Accessed May 12, 2017.
34. Califf RM, Robb MA, Bindman AB, Briggs JP, Collins FS, Conway PH, Coster TS, Cunningham FE, De Lew N, DeSalvo KB, Dymek C, Dzau VJ, Fleurence RL, Frank RG, Gaziano JM, Kaufmann P, Lauer M, Marks PW, McGinnis JM, Richards C, Selby JV, Shulkin DJ, Shuren J, Slavitt AM, Smith SR, Washington BV, White PJ, Woodcock J, Woodson J, Sherman RE. Transforming evidence generation to support health and health care decisions. N Engl J Med. 2016;375:2395-2400. doi: 10.1056/NEJMsb1610128.
35. Nystrom T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Novel oral glucose-lowering drugs compared to insulin are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycemia in type 2 diabetes patients [published online ahead of print January 24, 2017]. Diabetes Obes Metab. doi:10.1111/dom.12889.
36. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326. doi: 10.1056/NEJMoa1307684.
37. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752-772. doi: 10.1161/CIRCULATIONAHA.116.021887.
38. Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J. 2016;37:3192-3200. doi: 10.1093/eurheartj/ehw110.
39. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia. 2016;59:1333-1339. doi: 10.1007/s00125-016-3956-x.